We are happy to share that our client, Antoxerene, Inc., just received a $1.5 million investment to further develop technology that will help identify potential new pharmaceuticals for cancer and cellular-aging treatments.
Read more at: https://antoxerene.com/antoxerene-closes-1-5m-for-drug-discovery-in-pathways-of-aging/